Abli Therapeutics, Inc.

This study tested an experimental drug called IkT-148009 (risvodetinib) in 137 people with early, untreated Parkinson's disease. Participants took one of three doses or a placebo daily for 12 weeks. The goal was to check safety and see if the drug improves movement and daily livi…